|
|
Volumn 21, Issue 22, 2013, Pages 7155-7164
|
|
Targeting the human parasite Leishmania donovani: Discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series
|
|
Author keywords
HepG2 in vitro cytotoxicity; Imidazo 1,2 a pyridine; Leishmania donovani; Structure activity relationships
|
|
Indexed keywords
2 (BIPHENYL 4 YLSULFONYL)METHYL 6 BROMO 3 NITROIMIDAZO[1,2 A]PYRIDINE;
2 [(4 CHLOROPHENYLSULFONYL)METHYL] 6 IODO 3 NITROIMIDAZO[1,2 A]PYRIDINE;
2 [(4 CHLOROPHENYLSULFONYL)METHYL] 6 IODOIMIDAZO[1,2 A]PYRIDINE;
2 CHLOROMETHYL 6 IODO NITROIMIDAZO[1,2 A]PYRIDINE;
2 CHLOROMETHYL 6 IODOIMIDAZO[1,2 A]PYRIDINE;
2 PHENYLSULFONYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
3 NITRO 2 (PHENYLSULFONYLMETHYL) 6 (3,4,5 TRIMETHOXYPHENYL)IMIDAZO[1,2 A]PYRIDINE;
3 NITRO 2 PHENYLSULFONYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
3 NITROIMIDAZO[1,2 A]PYRIDINE DERIVATIVE;
6 BROMO 2 (4 CHLOROPHENYLSULFONYLMETHYL)IMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 (METHYLSULFONYLMETHYL) 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 (TOSYLMETHYL)IMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 [(4 BROMOPHENYLSULFONYL)METHYL] 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 [(4 CHLOROPHENYLSULFONYL)METHYL] 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 [(4 FLUOROPHENYLSULFONYL)METHYL] 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 [(4 IODOPHENYLSULFONYL)METHYL] 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 BROMO 2 [(4 METHOXYPHENYLSULFONYL)METHYL] 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 BROMO 3 NITRO 2 (4 TRIFLUOROMETHYL)PHENYLSULFONYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
6 CHLORO 2 (TOSYLMETHYL)IMIDAZO[1,2 A]PYRIDINE;
6 CHLORO 2 [(4 CHLOROPHENYLSULFONYL)METHYL] 3 NITROIMIDAZO[1,2 A]PYRIDINE;
6 CHLORO 2 [(4 CHLOROPHENYLSULFONYL)METHYL]IMIDAZO[1,2 A]PYRIDINE;
6 IODO 2 PHENYLSULFONYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
6 IODO 2 TOSYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
6 IODO 3 NITRO 2 PHENYLSULFONYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
6 IODO 3 TOSYLMETHYLIMIDAZO[1,2 A]PYRIDINE;
AMPHOTERICIN B;
ANTILEISHMANIAL AGENT;
MILTEFOSINE;
PENTAMIDINE;
UNCLASSIFIED DRUG;
AMASTIGOTE;
ANIMAL CELL;
ANTILEISHMANIAL ACTIVITY;
ANTIMICROBIAL ACTIVITY;
ARTICLE;
CELL LINE;
CELL STRAIN HEPG2;
CELL STRAIN J774A.1;
CONTROLLED STUDY;
DRUG POTENCY;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG TARGETING;
HUMAN;
HUMAN CELL;
IC 50;
IN VITRO STUDY;
LEISHMANIA DONOVANI;
LEISHMANIA INFANTUM;
MACROPHAGE;
MOUSE;
NONHUMAN;
PROMASTIGOTE;
STRUCTURE ACTIVITY RELATION;
LEISHMANIA DONOVANI;
MURINAE;
HEPG2 IN VITRO CYTOTOXICITY;
IMIDAZO[1,2-A]PYRIDINE;
LEISHMANIA DONOVANI;
STRUCTURE-ACTIVITY RELATIONSHIPS;
ANIMALS;
ANTIPROTOZOAL AGENTS;
CELL LINE;
CELL SURVIVAL;
DRUG EVALUATION, PRECLINICAL;
HEP G2 CELLS;
HUMANS;
IMIDAZOLES;
LEISHMANIA DONOVANI;
MICE;
PYRIDINES;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 84885869035
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2013.09.002 Document Type: Article |
|
Times cited : (38)
|
|
References (49)
|
